Donald E. Bobo, Jr. Sells 5,000 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $66.52 on Thursday. The stock has a market capitalization of $39.23 billion, a PE ratio of 9.60, a P/E/G ratio of 3.70 and a beta of 1.12. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The business has a fifty day moving average price of $67.47 and a two-hundred day moving average price of $76.51.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period last year, the firm earned $0.59 EPS. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the topic of a number of recent research reports. Barclays decreased their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Baird R W cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Evercore ISI reduced their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Canaccord Genuity Group dropped their price objective on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating for the company in a report on Friday, October 25th. Finally, TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and a consensus target price of $75.67.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its position in Edwards Lifesciences by 57.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after acquiring an additional 2,390,137 shares during the last quarter. CCLA Investment Management raised its holdings in Edwards Lifesciences by 100,739.7% in the 1st quarter. CCLA Investment Management now owns 1,406,714 shares of the medical research company’s stock valued at $134,092,000 after buying an additional 1,405,319 shares during the last quarter. Swedbank AB acquired a new stake in Edwards Lifesciences during the 1st quarter worth approximately $124,511,000. Bank of New York Mellon Corp grew its holdings in Edwards Lifesciences by 4.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after acquiring an additional 809,605 shares during the last quarter. Finally, Fisher Asset Management LLC increased its position in Edwards Lifesciences by 9.8% in the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock valued at $599,078,000 after acquiring an additional 806,705 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.